ReviewProtoplasma2018
Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.
Review in Protoplasma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.ACS central science · 2026Article
- Article
- In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.EJNMMI radiopharmacy and chemistry · 2024Article
- FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature.Cancers · 2024Review
- Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel, Switzerland) · 2023Review
- Activity-based bioluminescence probes for in vivo sensing applications.Current opinion in chemical biology · 2023Review
- Role and mechanism of fibroblast-activated protein-α expression on the surface of fibroblast-like synoviocytes in rheumatoid arthritis.Frontiers in immunology · 2023Review
- Mesenchymal stromal cells in the thymus.Inflammation and regeneration · 2022Review
- CT radiomics signature: a potential biomarker for fibroblast activation protein expression in patients with pancreatic ductal adenocarcinoma.Abdominal radiology (New York) · 2022Article
- Translational imaging of the fibroblast activation protein (FAP) using the new ligand [European journal of nuclear medicine and molecular imaging · 2022Article
- Review
- Distinctive CD26 Expression on CD4 T-Cell Subsets.Biomolecules · 2021Article
- Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence.World journal of diabetes · 2021Review
- The fibroblast: An emerging key player in thymic T cell selection.Immunological reviews · 2021Review
- Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.Journal of medicinal chemistry · 2021Article
- Dynamic PET/CT Imaging ofFrontiers in oncology · 2021Article
- Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects.Scientific reports · 2020Article
- Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours.Cancers · 2020Article
- Radiation Dosimetry and Biodistribution ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers. The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer. Furthermore, the stability and persistence of soluble DPP4 and FAP in the serum make them attractive candidate serology markers. This review summarises investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clinically useful tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.